

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

东曜药业

TOT BIOPHARM International Company Limited

東曜藥業股份有限公司

(Incorporated in Hong Kong with limited liability)

(Stock code: 1875)

PROPOSED CHANGE OF COMPANY ENGLISH NAME AND PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION

PROPOSED CHANGE OF COMPANY ENGLISH NAME

The Board announces that the Company proposes to change the English name of the Company from “TOT BIOPHARM International Company Limited” to “BioDlink International Company Limited”. The Change of Company English Name is subject to the approval by the Shareholders at the AGM by way of a special resolution and the relevant approval by the Registrar of Companies in Hong Kong.

PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION OF THE COMPANY

In view of the proposed Change of Company English Name, the Company also proposes to amend the Articles of Association to reflect the Change of Company English Name by replacing all references to “TOT BIOPHARM International Company Limited” with “BioDlink International Company Limited” in the Articles of Association. The proposed Amendments are subject to the passing of a special resolution of the Company at the AGM and shall take effect upon the Change of Company English Name becoming effective.

GENERAL

The AGM will be convened for the Shareholders to, among other things, consider and, if thought fit, approve the proposed Change of Company English Name and the proposed Amendments. A circular containing, amongst other things, details regarding the proposed Change of Company English Name and the proposed Amendments, together with the notice convening the AGM will be despatched to the Shareholders in due course.

PROPOSED CHANGE OF COMPANY ENGLISH NAME

The board of Directors (the “**Board**”) of TOT BIOPHARM International Company Limited (the “**Company**”) hereby announces that the Company proposes to change the English name of the Company from “TOT BIOPHARM International Company Limited” to “BioDlink International Company Limited” (the “**New Name**”, and such change, the “**Change of Company English Name**”).

A special resolution will be proposed at the annual general meeting of the Company for the year ended 31 December 2024 (the “**AGM**”) to be convened to, among other things, consider and, if thought fit, approve the Change of Company English Name.

CONDITIONS OF THE CHANGE OF COMPANY ENGLISH NAME

The Change of Company English Name is subject to satisfaction of the following conditions:

1. passing of the special resolution by the shareholders of the Company (the “**Shareholders**”) at the AGM approving the Change of Company English Name; and
2. the Registrar of Companies in Hong Kong approving the New Name and issuing a certificate of change of name.

Subject to the satisfaction of the conditions set out above, the Change of Company English Name will take effect from the date on which the certificate of change of name is issued by the Registrar of Companies in Hong Kong. The Company will carry out the necessary filing procedures with the Companies Registry in Hong Kong.

Subject to the confirmation by The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”), the English stock short name of the Company (the “**English Stock Short Name**”) for trading in the shares of the Company (the “**Shares**”) on the Stock Exchange will also be changed after the Proposed Change of Company English Name becomes effective.

REASON FOR THE CHANGE OF COMPANY ENGLISH NAME

The Board believes that the proposed New Name will better reflect the Company’s business strategy and can provide the Company with a more appropriate corporate image and identity which will benefit the Company’s future business development and is in the best interests of the Company and Shareholders as a whole.

EFFECTS OF THE CHANGE OF COMPANY ENGLISH NAME

The Change of Company English Name will not affect any rights of the existing holders of Shares or the Company’s daily business operation and its financial position. All the existing share certificates of the Company in issue bearing the existing name of the Company will, upon the Change of Company English Name becoming effective, continue to be evidence of title to such Shares and will continue to be valid for trading, settlement, registration and delivery of such Shares. There will not be any arrangement for free exchange of the existing share certificates of the Company for new share certificates printed in the New Name of the

Company. Upon the Change of Company English Name becoming effective, all new share certificates will only be issued in the New Name of the Company.

PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION

In view of the proposed Change of Company English Name, the Company also proposes to amend the amended and restated articles of association of the Company (the “**Articles of Association**”) to reflect the Change of Company English Name by replacing all references to “TOT BIOPHARM International Company Limited” with “BioDlink International Company Limited” in the Articles of Association (the “**Amendments**”). The proposed Amendments are subject to the passing of a special resolution of the Company at the AGM and shall take effect upon the Change of Company English Name becoming effective.

GENERAL

The AGM will be convened and held for the Shareholders to, among other things, consider and, if thought fit, approve the proposed Change of Company English Name and the proposed Amendments. A circular containing, among other things, details of the proposed Change of Company English Name and the proposed Amendments, together with the notice convening the AGM and the related proxy form will be despatched to the Shareholders in due course.

The Company will make further announcement(s) to inform the Shareholders of the poll results of the AGM, the effective date of the proposed Change of Company English Name and the new English Stock Short Name as and when appropriate.

By order of the Board
TOT BIOPHARM International Company Limited
Dr. Liu, Jun
Chief Executive Officer and Executive Director

Hong Kong, 28 May 2025

As at the date of this announcement, the executive director of the Company is Dr. Liu, Jun; the non-executive directors of the Company are Mr. Fu, Shan, Ms. Yeh-Huang, Chun-Ying and Dr. Liu, Weidong; and the independent non-executive directors of the Company are Ms. Sun, Hui, Mr. Zhang, Qing and Dr. Gu, Xuelin.